Audit: QRS - Maqui Berry for Health & Longevity
Audit conducted on 16/08/2026 00:18 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol doses, time-to-effect values, benefit/risk headings, contraindications, interactions, all 10 biomarker rows and the 5 qualitative markers trace to ER Therapeutic Protocol, Practical Considerations, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications and Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | At-a-glance carries the ER’s own “no side effect has been documented” and “Trials are small and short”; no cautious ER phrasing is replaced by firmer wording. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | All five avoid-populations remain in the Contraindications gate, not the Caution gate; speculative risks remain under the Speculative tier. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Nothing from ER Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates; gates draw solely from Key Interactions & Contraindications. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT IDs, expert names or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | The only attribution-like phrases (“mostly run by the sellers”, “the oxidative stress trial”, “the three-month trial”) are ER wording for the same fact. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Plain, measured, evidence-first register carried over from the ER, including its explicit sponsor-bias framing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified protocol and biomarker targets alongside accessible benefit/risk phrasing. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Content is stated as what was tested and measured, not as instruction to the reader. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Protocol cells state doses as studied (“once daily for at least 8 weeks”), not as directives; footer disclaimer intact. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should”, or “advised” in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to established biomarker and test names (HbA1c, HOMA-IR, hs-CRP, Schirmer’s test) required by the Monitoring table. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are label-level fragments; no sentence-level elaboration. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by full-text check for “you”/”your”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Functional-range biomarker targets and a 10-marker panel assume a proactive, self-quantifying reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Meal-anchored pre-meal dosing, clinician-performed Schirmer’s testing and an 8-week course are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplified “just take a supplement” framing; standardization and monitoring requirements are foregrounded. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance flags small, short, manufacturer-run trials; benefit tiers keep Medium as the ceiling. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Anti-aging” does not appear; the header carries the canonical “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Terms such as “blood sugar” and “blood-thinning drugs” are the ER’s own headings and glossary-style wording, carried verbatim; no colloquialisms are introduced. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All headings verified at lines 440, 477, 519, 539, 551, 571, 590, 594–596, 720; tier labels “Medium”/”Low”/”Speculative” unmodified at lines 525, 528, 531, 580, 583. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | 69 named spans present, covering header (4), at_a_glance, action_1–3 (9), time_1–3 (9), benefits (4), gates (2), risks (4), marker_1–10 (30), monitoring_cadence and qualitative_item_1–5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Every populated span maps to a checklist item; the non-variable template spans (website="evidence_review", website="audit", website="full_review") are untouched at lines 423, 426, 434. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section that feeds the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Ocular protocol”, “Glycemic protocol”, “Whole-food approach” and all eight interaction labels match the ER bold labels verbatim (ER lines 270–284, 312–316). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Time-to-effect labels (“Tear production”, “Glucose effect”, “Oxidative markers”) are the ER’s own nouns from the Time to effect bullet; biomarker names copied verbatim from the ER table. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Full-text scan returns no emoji; the ER’s “⚠️ Conflicted” marker was correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is reduced to label-level fragments; the remaining volume (10 biomarkers, 8 interactions, 5 qualitative markers) is the minimum mandated by items 9.5, 14.2 and 15.2, with no elaboration added. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2–14, immediately after the doctype at line 1 and before the template comment at line 16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in head or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: maqui_berry_2026-0825-2236_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0816-0010. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the actual filename on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All eight keys are single-line, trimmed; quoting used only where YAML requires it. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Maqui Berry for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Maqui Berry for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/16/2026”, the correct reformatting of 2026-0816-0010. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only title and the template subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Line 433 condenses the ER Conclusion (ER lines 440–444): the two human-tested claims, trial quality, sponsor bias, safety silence. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | “Chilean berry … delphinidin” (ER 440), “Two claims rest on human testing” (ER 440), “small and short” (ER 440), “mostly run by the sellers” (ER 444), “no side effect has been documented” (ER 442). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “delphinidin” is introduced in place as “the deep purple pigment”, mirroring the ER’s own gloss. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | Effects are described directionally (“raises”, “blunts”) with no numbers. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items come from the “Populations who should avoid Maqui Berry” list at ER lines 288–292. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations are present; none omitted, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 542–546, five <li> elements inside the span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing clause after the em-dash on the pregnancy bullet (“no safety or efficacy data exist…”) is stripped; no dashes remain in any item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “within 14 days” / “within 7 days”, “below 50 × 10⁹/L”, “without continuous or frequent glucose monitoring” and “Elaeocarpaceae-family” all preserved. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names five such populations and the section is correctly populated, not empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map one-to-one to the ER bullets at lines 270–284. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | No overlap with the five contraindication populations; the type 1 diabetes contraindication and the insulin/sulfonylurea interaction are distinct ER entries. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 554–561, eight <li> elements. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER mitigation and consequence clause (“Caution; additive glucose lowering…”, “Mitigation is…”) is stripped; only label plus drug examples remain. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named drug and supplement examples preserved, including “fish oil above 3 g/day”; the NSAID parenthetical is trimmed to its examples as permitted. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names eight interactions and the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from ER Therapeutic Protocol lines 312–316. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The ER’s two dosing protocols (ocular, glycemic) plus the whole-food alternative are the only implementation-level bullets; the remaining bullets are background rather than actions. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | “60 mg/day”, “180 mg/day, or 200 mg pre-meal” and “2–5 g/day berry powder” with their subs match ER lines 312, 314, 316 exactly in substance. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Tear production, glucose and oxidative markers are the only three time-to-effect facts in the ER (line 367). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Tear production and post-meal glucose are the two Medium-tier benefits and lead; oxidative markers (Low tier) follow. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “30 days”/”larger at 60 days”, “30–60 minutes”/”Acute, following a single dose”, “4 weeks”/”daily extract” all trace to ER line 367. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All ten items are the ER’s benefit headings from lines 140–194. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 521, 524, 527, 530. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; no Magnitude figures, p-values or sample sizes carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has no High tier and [benefits_high] carries style="display: none" with an explanatory comment (lines 521–523). |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven items are the ER’s risk headings from lines 216–252. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 573, 576, 579, 582. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each item is the bare ER heading; the ER’s Magnitude paragraphs (e.g., “60–90%” iron figure) are not carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER has neither a High nor a Medium risk tier; both spans carry style="display: none" with explanatory comments (lines 573–578). |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The table reproduces the ER Monitoring Protocol & Defining Success table at lines 397–408. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All ten ER biomarkers present with verbatim ranges and reasons: fasting glucose, HbA1c, fasting insulin, HOMA-IR, hs-CRP, oxidized LDL, LDL cholesterol, Schirmer’s test, tear break-up time, ferritin. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 714 condenses ER line 395: baseline, metabolic panel at 12 weeks then every 6–12 months, tear measurements at 8 weeks, ferritin annually. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items come from the ER’s “Qualitative markers worth tracking” list at lines 412–416. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers present; only the trailing attribution on the fifth (“the outcome suggested by the heart rate variability trial”) is stripped. |
Issues 16/08/2026 00:18
Pass rate 100.00%. No issues found.